• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Kodiak Sciences (KOD) Could Be 40% Undervalued After Its $350 Million Equity Offering

    Simply Wall St·10/24/2026 12:28:37
    語音播報

    Kodiak Sciences (KOD) has moved to raise fresh capital, filing a universal shelf registration and launching a US$350 million at-the-market follow-on equity offering that could reshape its funding profile.

    Investors have already been pricing in a lot of expectation around Kodiak Sciences, with the share price at US$87.63 and a 30 day share price return of 178.01% on top of a 236.78% year to date gain. The 1 year total shareholder return of 368.86% and a very large 3 year total shareholder return point to strong momentum. This new capital raise now tests that momentum by shifting attention back to dilution risk and execution on the clinical pipeline.

    Scan how other high momentum biotech and healthcare names compare on funding, dilution risk, and recent performance using our hand picked 34 healthcare AI stocks alongside Kodiak Sciences.

    The share price surge and fresh equity capacity now collide for Kodiak Sciences. Does that mix still leave enough upside for new buyers once valuation is brought back into focus?

    Most Popular Narrative: 40% Undervalued

    The most followed narrative on Kodiak Sciences pegs fair value at $145 per share, well above the recent $87.63 close. This puts the capital raise against a backdrop of a stock already framed as materially undervalued by bullish analysts using a 7.4% discount rate.

    The assumed bullish price target for Kodiak Sciences is $145.0, which represents up to two standard deviations above the consensus price target of $121.67. This valuation is based on what can be assumed as the expectations of Kodiak Sciences's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.

    See why 0 investors see Kodiak Sciences as 40% undervalued.

    Result: Fair Value of $145 (UNDERVALUED)

    Still, Kodiak Sciences faces clear pressure points, including the risk that key Phase 3 trials miss endpoints and that further equity funding leaves shareholders with heavier dilution than analysts currently model.

    Find out about the key risks to this Kodiak Sciences narrative.

    Next Steps

    Sentiment around Kodiak Sciences is pulled in two directions, with sharp enthusiasm on one side and clear caution on the other. Move quickly to review the underlying data, weigh both the potential risks and the possible upside, and ground your own view in the 3 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Kodiak Sciences?

    If Kodiak Sciences has your attention, do not stop there. Broaden your watchlist with data driven ideas that could sharpen your next move.